Does the media prefer VRCA or ZURA?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Zura Bio's score of -0.56 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media favor LYEL or VRCA?

In the previous week, Lyell Immunopharma had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Lyell Immunopharma and 2 mentions for Verrica Pharmaceuticals. Lyell Immunopharma's average media sentiment score of 0.23 beat Verrica Pharmaceuticals' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VRCA or GLSI?

In the previous week, Greenwich LifeSciences had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -0.85 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor XFOR or VRCA?

In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 2 articles in the media. X4 Pharmaceuticals' average media sentiment score of 0.33 beat Verrica Pharmaceuticals' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Verrica Pharmaceuticals (VRCA) Competitors

$5.99 -0.05 (-0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$6.00 +0.00 (+0.08%)

As of 04:10 PM Eastern

Compare

VRCA vs. ZURA, LYEL, CMPX, GLSI, and XFOR

Should you buy Verrica Pharmaceuticals stock or one of its competitors? MarketBeat compares Verrica Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verrica Pharmaceuticals include Zura Bio (ZURA), Lyell Immunopharma (LYEL), Compass Therapeutics (CMPX), Greenwich LifeSciences (GLSI), and X4 Pharmaceuticals (XFOR). These companies are all part of the "pharmaceutical products" industry.

How does Verrica Pharmaceuticals compare to Zura Bio?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Zura Bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Verrica Pharmaceuticals presently has a consensus target price of $14.50, indicating a potential upside of 142.07%. Zura Bio has a consensus target price of $10.75, indicating a potential upside of 204.53%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Zura Bio has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Zura Bio's return on equity of -55.74% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Zura Bio	N/A	-55.74%	-48.07%

Verrica Pharmaceuticals has higher revenue and earnings than Zura Bio. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.89	-$17.89M	-$1.03	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 22.1% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 2 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Zura Bio's score of -0.56 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Verrica Pharmaceuticals and Zura Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Lyell Immunopharma?

Lyell Immunopharma (NASDAQ:LYEL) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Verrica Pharmaceuticals has higher revenue and earnings than Lyell Immunopharma. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40K	7,179.81	-$274.45M	-$13.80	N/A
Verrica Pharmaceuticals	$35.58M	2.89	-$17.89M	-$1.03	N/A

Lyell Immunopharma presently has a consensus price target of $43.00, indicating a potential upside of 249.31%. Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 142.07%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Lyell Immunopharma is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 6.2% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lyell Immunopharma had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 6 mentions for Lyell Immunopharma and 2 mentions for Verrica Pharmaceuticals. Lyell Immunopharma's average media sentiment score of 0.23 beat Verrica Pharmaceuticals' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lyell Immunopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lyell Immunopharma has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Summary

Lyell Immunopharma beats Verrica Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Verrica Pharmaceuticals has higher revenue and earnings than Compass Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	427.98	-$66.49M	-$0.41	N/A
Verrica Pharmaceuticals	$35.58M	2.89	-$17.89M	-$1.03	N/A

Compass Therapeutics currently has a consensus price target of $12.91, suggesting a potential upside of 539.06%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 142.07%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Compass Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Compass Therapeutics had 3 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for Compass Therapeutics and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Compass Therapeutics' score of -0.08 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Compass Therapeutics' return on equity of -39.75% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-39.75%	-35.29%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Compass Therapeutics beats Verrica Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Greenwich LifeSciences?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Verrica Pharmaceuticals currently has a consensus price target of $14.50, suggesting a potential upside of 142.07%. Greenwich LifeSciences has a consensus price target of $47.50, suggesting a potential upside of 119.40%. Given Verrica Pharmaceuticals' higher possible upside, equities analysts plainly believe Verrica Pharmaceuticals is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Verrica Pharmaceuticals has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.89	-$17.89M	-$1.03	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

In the previous week, Greenwich LifeSciences had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Greenwich LifeSciences and 2 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -0.85 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Greenwich LifeSciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Greenwich LifeSciences' return on equity of -941.15% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Greenwich LifeSciences on 9 of the 13 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

X4 Pharmaceuticals currently has a consensus target price of $9.38, indicating a potential upside of 152.70%. Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 142.07%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe X4 Pharmaceuticals is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has higher revenue and earnings than X4 Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	9.97	-$79.20M	-$4.54	N/A
Verrica Pharmaceuticals	$35.58M	2.89	-$17.89M	-$1.03	N/A

Verrica Pharmaceuticals has a net margin of -47.97% compared to X4 Pharmaceuticals' net margin of -1,106.30%. X4 Pharmaceuticals' return on equity of -94.90% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 2 articles in the media. X4 Pharmaceuticals' average media sentiment score of 0.33 beat Verrica Pharmaceuticals' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

X4 Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Summary

X4 Pharmaceuticals and Verrica Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$103.76M	$2.94B	$6.43B	$12.05B
Dividend Yield	N/A	1.69%	2.67%	5.56%
P/E Ratio	N/A	17.68	23.75	23.75
Price / Sales	2.89	296.71	479.99	83.74
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	3.86	3.83	10.28	6.78
Net Income	-$17.89M	$75.85M	$3.57B	$337.51M
7 Day Performance	1.53%	-4.52%	-1.43%	-2.72%
1 Month Performance	-25.03%	-5.85%	3.27%	1.87%
1 Year Performance	-2.06%	15.31%	23.37%	26.61%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	2.3902 of 5 stars	$5.99 -0.8%	$14.50 +142.1%	-1.2%	$103.76M	$35.58M	N/A	40
ZURA Zura Bio	2.7135 of 5 stars	$4.24 -1.4%	$10.75 +153.5%	+169.8%	$402.29M	N/A	N/A	3	News Coverage Positive News
LYEL Lyell Immunopharma	2.9086 of 5 stars	$17.15 -1.0%	$43.00 +150.7%	-6.2%	$400.11M	$40K	N/A	270	News Coverage Analyst Forecast
CMPX Compass Therapeutics	2.3312 of 5 stars	$2.22 -6.7%	$12.91 +481.5%	-18.4%	$399.80M	$850K	N/A	20
GLSI Greenwich LifeSciences	1.3559 of 5 stars	$28.51 +8.9%	$47.50 +66.6%	+130.3%	$394.86M	N/A	N/A	3	Upcoming Earnings Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. ZURA, LYEL, CMPX, GLSI, and XFOR

How does Verrica Pharmaceuticals compare to Zura Bio?

Summary

How does Verrica Pharmaceuticals compare to Lyell Immunopharma?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Greenwich LifeSciences?

Summary

How does Verrica Pharmaceuticals compare to X4 Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. ZURA, LYEL, CMPX, GLSI, and XFOR

How does Verrica Pharmaceuticals compare to Zura Bio?

Which has more volatility & risk, VRCA or ZURA?

Do analysts rate VRCA or ZURA?

Is VRCA or ZURA more profitable?

Which has stronger earnings and valuation, VRCA or ZURA?

Do institutionals & insiders believe in VRCA or ZURA?

Does the media prefer VRCA or ZURA?

Summary

How does Verrica Pharmaceuticals compare to Lyell Immunopharma?

Is LYEL or VRCA more profitable?

Which has preferable earnings & valuation, LYEL or VRCA?

Do analysts rate LYEL or VRCA?

Do insiders & institutionals have more ownership in LYEL or VRCA?

Does the media favor LYEL or VRCA?

Which has more risk and volatility, LYEL or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Compass Therapeutics?

Which has stronger earnings & valuation, CMPX or VRCA?

Do analysts recommend CMPX or VRCA?

Does the media refer more to CMPX or VRCA?

Which has more risk & volatility, CMPX or VRCA?

Is CMPX or VRCA more profitable?

Do insiders and institutionals believe in CMPX or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Greenwich LifeSciences?

Do insiders and institutionals hold more shares of VRCA or GLSI?

Do analysts rate VRCA or GLSI?

Which has stronger valuation and earnings, VRCA or GLSI?

Does the media prefer VRCA or GLSI?

Is VRCA or GLSI more profitable?

Which has more volatility & risk, VRCA or GLSI?

Summary

How does Verrica Pharmaceuticals compare to X4 Pharmaceuticals?

Do analysts rate XFOR or VRCA?

Which has better earnings and valuation, XFOR or VRCA?

Is XFOR or VRCA more profitable?

Do institutionals and insiders believe in XFOR or VRCA?

Does the media favor XFOR or VRCA?

Which has more volatility and risk, XFOR or VRCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools